Gender-related disparities in non-small cell lung cancer

Cancer Letters

Volumn 298, Issue 1, 2010, Pages 1-8

  Paggi, Marco G ^a   Vona, Rosa ^b   Abbruzzese, Claudia ^a   Malorni, Walter ^b,c  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c Istituto San Raffaele Sulmona   (Italy)

Author keywords

Apoptosis; Autophagy; Cancer; Estrogens; Gender; Non small cell lung cancer

Indexed keywords

AROMATASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; GLUTATHIONE TRANSFERASE;

AUTOPHAGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CIGARETTE SMOKING; CONDYLOMA ACUMINATUM; DRUG SENSITIVITY; ENVIRONMENTAL FACTOR; EPIGENETICS; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS POTENTIAL; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SHORT SURVEY; SURVIVAL RATE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; FEMALE; GENETICS; LUNG NEOPLASMS; MALE; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROGNOSIS; SEX FACTORS;

EID: 77956908373     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.08.009     Document Type: Review

References (99)

1. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. New Engl. J. Med. 2008, 359:1367-1380.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
3. Boffetta P. Epidemiology of environmental and occupational cancer. Oncogene 2004, 23:6392-6403.
4. Henschke C.I., Yankelevitz D.F., Libby D.M., Pasmantier M.W., Smith J.P., Miettinen O.S. Survival of patients with stage I lung cancer detected on CT screening. New Engl. J. Med. 2006, 355:1763-1771.
5. Welch H.G., Woloshin S., Schwartz L.M., Gordis L., Gotzsche P.C., Harris R., Kramer B.S., Ransohoff D.F. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch. Intern. Med. 2007, 167:2289-2295.
6. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
7. Melief C.J. Cancer: immune pact with the enemy. Nature 2007, 450:803-804.
8. Sun S., Schiller J.H., Gazdar A.F. Lung cancer in never smokers - a different disease. Nat. Rev. Cancer 2007, 7:778-790.
9. Freedman N.D., Leitzmann M.F., Hollenbeck A.R., Schatzkin A., Abnet C.C. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol. 2008, 9:649-656.
10. Subramanian J., Govindan R. Lung cancer in never smokers: a review. J. Clin. Oncol. 2007, 25:561-570.
11. Wakelee H.A., Chang E.T., Gomez S.L., Keegan T.H., Feskanich D., Clarke C.A., Holmberg L., Yong L.C., Kolonel L.N., Gould M.K., West D.W. Lung cancer incidence in never smokers. J. Clin. Oncol. 2007, 25:472-478.
12. Gazdar A.F., Thun M.J. Lung cancer, smoke exposure, and sex. J. Clin. Oncol. 2007, 25:469-471.
13. Hsu L.H., Chu N.M., Liu C.C., Tsai S.Y., You D.L., Ko J.S., Lu M.C., Feng A.C. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor?. Lung Cancer 2009, 66:262-267.
14. Thun M.J., Henley S.J., Burns D., Jemal A., Shanks T.G., Calle E.E. Lung cancer death rates in lifelong nonsmokers. J. Natl. Cancer Inst. 2006, 98:691-699.
15. Thun M.J., Hannan L.M., Adams-Campbell L.L., Boffetta P., Buring J.E., Feskanich D., Flanders W.D., Jee S.H., Katanoda K., Kolonel L.N., Lee I.M., Marugame T., Palmer J.R., Riboli E., Sobue T., Avila-Tang E., Wilkens L.R., Samet J.M. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med. 2008, 5:e185.
16. Rudin C.M., Avila-Tang E., Samet J.M. Lung cancer in never smokers: a call to action. Clin. Cancer Res. 2009, 15:5622-5625.
17. Samet J.M., Avila-Tang E., Boffetta P., Hannan L.M., Olivo-Marston S., Thun M.J., Rudin C.M. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin. Cancer Res. 2009, 15:5626-5645.
18. Rudin C.M., Avila-Tang E., Harris C.C., Herman J.G., Hirsch F.R., Pao W., Schwartz A.G., Vahakangas K.H., Samet J.M. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin. Cancer Res. 2009, 15:5646-5661.
19. Toyooka S., Tokumo M., Shigematsu H., Matsuo K., Asano H., Tomii K., Ichihara S., Suzuki M., Aoe M., Date H., Gazdar A.F., Shimizu N. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res. 2006, 66:1371-1375.
20. Lam W.K. Lung cancer in Asian women - the environment and genes. Respirology 2005, 10:408-417.
21. Cheng Y.W., Hsieh L.L., Lin P.P., Chen C.P., Chen C.Y., Lin T.S., Su J.M., Lee H. Gender difference in DNA adduct levels among nonsmoking lung cancer patients. Environ. Mol. Mutagen. 2001, 37:304-310.
22. Patel J.D. Lung cancer in women. J. Clin. Oncol. 2005, 23:3212-3218.
23. Zell J.A., Ou S.H., Ziogas A., Anton-Culver H. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J. Clin. Oncol. 2005, 23:8396-8405.
24. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., Krug L.M., Pao W., Rizvi N., Pizzo B., Tyson L., Venkatraman E., Ben-Porat L., Memoli N., Zakowski M., Rusch V., Heelan R.T. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 2004, 22:1103-1109.
25. Shafer D., Albain K. Lung cancer outcomes in women. Semin. Oncol. 2009, 36:532-541.
26. Siegfried J.M. Women and lung cancer: does oestrogen play a role?. Lancet Oncol. 2001, 2:506-513.
27. Siegfried J.M., Hershberger P.A., Stabile L.P. Estrogen receptor signaling in lung cancer. Semin. Oncol. 2009, 36:524-531.
28. Ivanova M.M., Mazhawidza W., Dougherty S.M., Klinge C.M. Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. Am. J. Respir. Cell Mol. Biol. 2010, 42:320-330.
29. Wei Q., Cheng L., Amos C.I., Wang L.E., Guo Z., Hong W.K., Spitz M.R. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J. Natl. Cancer Inst. 2000, 92:1764-1772.
30. M. Kirsch-Volders, S. Bonassi, Z. Herceg, A. Hirvonen, L. Moller, D.H. Phillips, Gender-related differences in response to mutagens and carcinogens, 2010 (Mutagenesis).
31. Koutras A., Giannopoulou E., Kritikou I., Antonacopoulou A., Evans T.R., Papavassiliou A.G., Kalofonos H. Antiproliferative effect of exemestane in lung cancer cells. Mol. Cancer 2009, 8:109.
32. Mah V., Seligson D.B., Li A., Marquez D.C., Wistuba I.I., Elshimali Y., Fishbein M.C., Chia D., Pietras R.J., Goodglick L. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res. 2007, 67:10484-10490.
33. Abe K., Miki Y., Ono K., Mori M., Kakinuma H., Kou Y., Kudo N., Koguchi M., Niikawa H., Suzuki S., Evans D.B., Sugawara S., Suzuki T., Sasano H. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum. Pathol. 2010, 41:190-198.
34. Weinberg O.K., Marquez-Garban D.C., Fishbein M.C., Goodglick L., Garban H.J., Dubinett S.M., Pietras R.J. Aromatase inhibitors in human lung cancer therapy. Cancer Res. 2005, 65:11287-11291.
35. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002, 110:669-672.
36. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 2008, 8:915-928.
37. Mattarocci S., Abbruzzese C., Mileo A.M., Visca P., Antoniani B., Alessandrini G., Facciolo F., Felsani A., Radulescu R.T., Paggi M.G. Intracellular presence of insulin and its phosphorylated receptor in non-small cell lung cancer. J. Cell. Physiol. 2009, 221:766-770.
38. Rosell R., Ichinose Y., Taron M., Sarries C., Queralt C., Mendez P., Sanchez J.M., Nishiyama K., Moran T., Cirauqui B., Mate J.L., Besse B., Reguart N., Perez M., Sanchez J.J. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 2005, 50:25-33.
39. Janne P.A., Engelman J.A., Johnson B.E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol. 2005, 23:3227-3234.
40. Sequist L.V., Bell D.W., Lynch T.J., Haber D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 2007, 25:587-595.
41. Toyooka S., Matsuo K., Shigematsu H., Kosaka T., Tokumo M., Yatabe Y., Ichihara S., Inukai M., Suehisa H., Soh J., Kiura K., Fong K.M., Lee H., Wistuba I.I., Gazdar A.F., Mitsudomi T., Date H. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin. Cancer Res. 2007, 13:5763-5768.
42. Harichand-Herdt S., Ramalingam S.S. Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. Semin. Oncol. 2009, 36:572-580.
43. Tanaka T., Matsuoka M., Sutani A., Gemma A., Maemondo M., Inoue A., Okinaga S., Nagashima M., Oizumi S., Uematsu K., Nagai Y., Moriyama G., Miyazawa H., Ikebuchi K., Morita S., Kobayashi K., Hagiwara K. Frequency of and variables associated with the EGFR mutation and its subtypes. Int. J. Cancer 2010, 126:651-655.
44. Raso M.G., Behrens C., Herynk M.H., Liu S., Prudkin L., Ozburn N.C., Woods D.M., Tang X., Mehran R.J., Moran C., Lee J.J., Wistuba I.I. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin. Cancer Res. 2009, 15:5359-5368.
45. Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., Siegfried J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 2005, 65:1459-1470.
46. Traynor A.M., Schiller J.H., Stabile L.P., Kolesar J.M., Eickhoff J.C., Dacic S., Hoang T., Dubey S., Marcotte S.M., Siegfried J.M. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 2009, 64:51-59.
47. McCance D.J., Kopan R., Fuchs E., Laimins L.A. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc. Natl. Acad. Sci. USA 1988, 85:7169-7173.
48. Lavia P., Mileo A.M., Giordano A., Paggi M.G. Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability. Oncogene 2003, 22:6508-6516.
49. Munger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., Grace M., Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 2004, 78:11451-11460.
50. zur Hausen H. The search for infectious causes of human cancers: where and why (nobel lecture). Angew. Chem. Int. Ed. Engl. 2009, 48:5798-5808.
51. Munger K., Basile J.R., Duensing S., Eichten A., Gonzalez S.L., Grace M., Zacny V.L. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001, 20:7888-7898.
52. Helt A.M., Galloway D.A. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 2003, 24:159-169.
53. Felsani A., Mileo A.M., Paggi M.G. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 2006, 25:5277-5285.
54. Duensing S., Munger K. Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability. Oncogene 2002, 21:6241-6248.
55. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2:342-350.
56. Severino A., Abbruzzese C., Manente L., Avivar Valderas A., Mattarocci S., Federico A., Starace G., Chersi A., Mileo A.M., Paggi M.G. Human papillomavirus-16 E7 interacts with Siva-1 and modulates apoptosis in HaCaT human immortalized keratinocytes. J. Cell. Physiol. 2007, 212:118-125.
57. Whiteside M.A., Siegel E.M., Unger E.R. Human papillomavirus and molecular considerations for cancer risk. Cancer 2008, 113:2981-2994.
58. Cheng Y.W., Wu M.F., Wang J., Yeh K.T., Goan Y.G., Chiou H.L., Chen C.Y., Lee H. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res. 2007, 67:10686-10693.
59. Cheng Y.W., Lee H., Shiau M.Y., Wu T.C., Huang T.T., Chang Y.H. Human papillomavirus type 16/18 up-regulates the expression of interleukin-6 and antiapoptotic Mcl-1 in non-small cell lung cancer. Clin. Cancer Res. 2008, 14:4705-4712.
60. Mileo A.M., Abbruzzese C., Mattarocci S., Bellacchio E., Pisano P., Federico A., Maresca V., Picardo M., Giorgi A., Maras B., Schinina M.E., Paggi M.G. Human papillomavirus-16 E7 interacts with glutathione S-transferase P1 and enhances its role in cell survival. PLoS ONE 2009, 4:e7254.
61. Willey J.C., Broussoud A., Sleemi A., Bennett W.P., Cerutti P., Harris C.C. Immortalization of normal human bronchial epithelial cells by human papillomaviruses 16 or 18. Cancer Res. 1991, 51:5370-5377.
62. Syrjanen K.J. HPV infections and lung cancer. J. Clin. Pathol. 2002, 55:885-891.
63. Li Y.J., Tsai Y.C., Chen Y.C., Christiani D.C. Human papilloma virus and female lung adenocarcinoma. Semin. Oncol. 2009, 36:542-552.
64. Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J. Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma. Cancer Sci. 2010, 101:1891-1896.
65. Planchard D., Loriot Y., Goubar A., Commo F., Soria J.C. Differential expression of biomarkers in men and women. Semin. Oncol. 2009, 36:553-565.
66. Srinivasan M., Taioli E., Ragin C.C. Human papillomavirus type 16 and 18 in primary lung cancers - a meta-analysis. Carcinogenesis 2009, 30:1722-1728.
67. Cheng Y.W., Chiou H.L., Sheu G.T., Hsieh L.L., Chen J.T., Chen C.Y., Su J.M., Lee H. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res. 2001, 61:2799-2803.
68. Castillo A., Aguayo F., Koriyama C., Shuyama K., Akiba S., Herrera-Goepfert R., Carrascal E., Klinge G., Sanchez J., Eizuru Y. Human papillomavirus in lung carcinomas among three Latin American countries. Oncol. Rep. 2006, 15:883-888.
69. Aguayo F., Castillo A., Koriyama C., Higashi M., Itoh T., Capetillo M., Shuyama K., Corvalan A., Eizuru Y., Akiba S. Human papillomavirus-16 is integrated in lung carcinomas: a study in Chile. Br. J. Cancer 2007, 97:85-91.
70. Perez-Soler R. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Oncogene 2009, 28(Suppl. 1):S38-S45.
71. Novello S., Vavala T. Lung cancer and women. Future Oncol. 2008, 4:705-716.
72. Egloff A.M., Weissfeld J., Land S.R., Finn O.J. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann. N.Y. Acad. Sci. 2005, 1062:29-40.
73. P. Boyle, C.J. Chapman, S. Holdenrieder, A. Murray, C. Robertson, W.C. Wood, P. Maddison, G. Healey, G.H. Fairley, A.C. Barnes, J.F. Robertson, Clinical validation of an autoantibody test for lung cancer, Ann. Oncol. 30 (July) 2010 (Epub ahead of print).
74. P. Maddison, A. Thorpe, P. Silcocks, J.F. Robertson, C.J. Chapman, Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer, Lung Cancer April 3, 2010 (Epub ahead of print).
75. Y. Naito, K. Goto, K. Nagai, G. Ishii, M. Nishimura, J. Yoshida, T. Hishida, Y. Nishiwaki, Vascular invasion is a strong prognostic factor after complete resection of node-negative non-small cell lung cancer, Chest July 1, 2010 (Epub ahead of print).
76. Lin Q., Li M., Shen Z.Y., Xiong L.W., Pan X.F., Gen J.F., Bao G.L., Sha H.F., Feng J.X., Ji C.Y., Chen M. Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer. Jpn. J. Clin. Oncol. 2010, 40:670-676.
77. Ortona E., Margutti P., Matarrese P., Franconi F., Malorni W. Redox state, cell death and autoimmune diseases: a gender perspective. Autoimmun. Rev. 2008, 7:579-584.
78. Sakaguchi S., Goto H., Hanibuchi M., Otsuka S., Ogino H., Kakiuchi S., Uehara H., Yano S., Nishioka Y., Sone S. Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice. Clin. Exp. Metast. 2010, 27:351-359.
79. Skov B.G., Fischer B.M., Pappot H. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 2008, 59:88-94.
80. Carey M.A., Card J.W., Voltz J.W., Arbes S.J., Germolec D.R., Korach K.S., Zeldin D.C. It's all about sex: gender, lung development and lung disease. Trends Endocrinol. Metab. 2007, 18:308-313.
81. Pierdominici M., Maselli A., Colasanti T., Giammarioli A.M., Delunardo F., Vacirca D., Sanchez M., Giovannetti A., Malorni W., Ortona E. Estrogen receptor profiles in human peripheral blood lymphocytes. Immunol. Lett. 2010, 132:79-85.
82. Wang F., Feng M., Xu P., Xiao H., Niu P., Yang X., Bai Y., Peng Y., Yao P., Tan H., Tanguay R.M., Wu T. The level of Hsp27 in lymphocytes is negatively associated with a higher risk of lung cancer. Cell Stress Chaperones 2009, 14:245-251.
83. O'Mahony D., Kummar S., Gutierrez M.E. Non-small-cell lung cancer vaccine therapy: a concise review. J. Clin. Oncol. 2005, 23:9022-9028.
84. Maselli A., Matarrese P., Straface E., Canu S., Franconi F., Malorni W. Cell sex: a new look at cell fate studies. FASEB J. 2009, 23:978-984.
85. Malorni W., Straface E., Matarrese P., Ascione B., Coinu R., Canu S., Galluzzo P., Marino M., Franconi F. Redox state and gender differences in vascular smooth muscle cells. FEBS Lett. 2008, 582:635-642.
86. Dowling R.J., Topisirovic I., Fonseca B.D., Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim. Biophys. Acta 2010, 1804:433-439.
87. Gridelli C., Maione P., Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 2008, 13:139-147.
88. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., el-Deiry W.S., Golstein P., Green D.R., Hengartner M., Knight R.A., Kumar S., Lipton S.A., Malorni W., Nunez G., Peter M.E., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ. 2009, 16(2009):3-11.
89. Straface E., Vona R., Gambardella L., Ascione B., Marino M., Bulzomi P., Canu S., Coinu R., Rosano G., Malorni W., Franconi F. Cell sex determines anoikis resistance in vascular smooth muscle cells. FEBS Lett. 2009, 583:3448-3454.
90. Du L., Hickey R.W., Bayir H., Watkins S.C., Tyurin V.A., Guo F., Kochanek P.M., Jenkins L.W., Ren J., Gibson G., Chu C.T., Kagan V.E., Clark R.S. Starving neurons show sex difference in autophagy. J. Biol. Chem. 2009, 284:2383-2396.
91. Malorni W., Campesi I., Straface E., Vella S., Franconi F. Redox features of the cell: a gender perspective. Antioxid. Redox. Signal. 2007, 9:1779-1801.
92. Yang J., Wang L., Chen Z., Shen Z.Q., Jin M., Wang X.W., Zheng Y., Qiu Z.G., Wang J.F., Li J.W. Antioxidant intervention of smoking-induced lung tumor in mice by vitamin E and quercetin BMC. Cancer 2008, 8:383.
93. Mostertz W., Stevenson M., Acharya C., Chan I., Walters K., Lamlertthon W., Barry W., Crawford J., Nevins J., Potti A. Age- and sex-specific genomic profiles in non-small cell lung cancer. JAMA 2010, 303:535-543.
94. Hampton T. Lung cancer mortality higher in women who used combination hormone therapy. JAMA 2009, 302:615-616.
95. Chlebowski R.T., Schwartz A.G., Wakelee H., Anderson G.L., Stefanick M.L., Manson J.E., Rodabough R.J., Chien J.W., Wactawski-Wende J., Gass M., Kotchen J.M., Johnson K.C., O'Sullivan M.J., Ockene J.K., Chen C., Hubbell F.A. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009, 374:1243-1251.
96. Castelao J.E., Yuan J.M., Skipper P.L., Tannenbaum S.R., Gago-Dominguez M., Crowder J.S., Ross R.K., Yu M.C. Gender- and smoking-related bladder cancer risk. J. Natl. Cancer Inst. 2001, 93:538-545.
97. McGrath M., Michaud D.S., De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am. J. Epidemiol. 2006, 163:236-244.
98. Karagas M.R., Park S., Warren A., Hamilton J., Nelson H.H., Mott L.A., Kelsey K.T. Gender, smoking, glutathione-S-transferase variants and bladder cancer incidence: a population-based study. Cancer Lett. 2005, 219:63-69.
99. Blackford A., Parmigiani G., Kensler T.W., Wolfgang C., Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Eshleman J.R., Goggins M., Jaffee E.M., Iacobuzio-Donahue C.A., Maitra A., Klein A., Cameron J.L., Olino K., Schulick R., Winter J., Vogelstein B., Velculescu V.E., Kinzler K.W., Hruban R.H. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res. 2009, 69:3681-3688.